Roivant Sciences Ltd (ROIV)
Return on total capital
| Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | — | 4,288,210 | -1,196,870 | -922,638 | -1,070,900 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 4,687,600 | 5,968,580 | 1,157,770 | 1,656,940 | 1,797,790 |
| Return on total capital | 0.00% | 71.85% | -103.38% | -55.68% | -59.57% |
March 31, 2025 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $4,687,600K)
= 0.00%
Roivant Sciences Ltd has shown varying trends in its return on total capital over the years.
- As of March 31, 2021, the return on total capital was -59.57%, indicating that the company's capital investment did not generate positive returns.
- The performance improved slightly by March 31, 2022, with the return on total capital standing at -55.68%. However, it remained in negative territory.
- The return on total capital deteriorated significantly by March 31, 2023, plummeting to -103.38%, reflecting a substantial decline in capital efficiency.
- There was a notable turnaround by March 31, 2024, where the return on total capital surged to 71.85%, indicating a strong improvement in the company's capital utilization and profitability.
- The data for March 31, 2025, is missing and therefore, it is not possible to analyze the return on total capital for that period.
Overall, Roivant Sciences Ltd has experienced fluctuations in its return on total capital, with significant improvements witnessed in certain years, notably in 2024, which could signify enhanced operational efficiency and profitability.
Peer comparison
Mar 31, 2025